S. 1131 · 118th Congress

Drug Price Transparency Act of 2023

Stage
In committee
Sponsor
Mike Braun
Introduced
2023-03-30
Latest action
2023-03-30 · Introduced in Senate

Summary

Drug Price Transparency Act of 2023

This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws. Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.